A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents

Trial Profile

A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Panobinostat (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms PANORAMA-3
  • Sponsors Novartis
  • Most Recent Events

    • 30 May 2017 Planned primary completion date changed from 15 Dec 2022 to 17 Apr 2019.
    • 15 May 2017 Planned End Date changed from 3 May 2022 to 15 Dec 2022.
    • 15 May 2017 Planned primary completion date changed from 3 May 2022 to 15 Dec 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top